There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC) and Cidara Therapeutics (CDTX) with bullish sentiments.
Atricure (ATRC)
Needham analyst Michael Matson reiterated a Buy rating on Atricure yesterday and set a price target of $39. The company’s shares closed last Monday at $30.62.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.0% and a 62.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $38, representing a 23.5% upside. In a report issued on July 30, BTIG also maintained a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
Cidara Therapeutics (CDTX)
In a report released yesterday, Alan Carr from Needham reiterated a Buy rating on Cidara Therapeutics, with a price target of $10. The company’s shares closed last Monday at $1.32, close to its 52-week low of $1.23.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.3% and a 41.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
Cidara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
